Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.39 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11579749 | 0.88 | LDHA (0.43) | LDHAACHEL3MBTL1PPARGPPARA | |
| SCHEMBL11400130 | 0.88 | LDHA (0.43) | LDHAACHEL3MBTL1PPARGPPARA | |
| SCHEMBL10519344 | 0.88 | LDHA (0.43) | LDHAACHEL3MBTL1PPARGPPARA | |
| SCHEMBL2544891 | 0.88 | ALDH1A1 (0.39) | L3MBTL1PPARGPPARAMEN1KMT2A | |
| SCHEMBL8893537 | 0.81 | LDHA (0.44) | LDHAACHEL3MBTL1PPARGPPARA | |
| SCHEMBL11148899 | 0.81 | LDHA (0.43) | LDHAACHEL3MBTL1PPARGPPARA | |
| SCHEMBL24291657 | 0.80 | ALDH1A1 (0.43) | LDHAACHEL3MBTL1TDP1MEN1 | |
| SCHEMBL16991845 | 0.78 | ALDH1A1 (0.49) | LDHAACHEL3MBTL1PPARGPPARA | |
| SCHEMBL25609121 | 0.78 | ALDH1A1 (0.41) | LDHAACHEL3MBTL1PPARGPPARA | |
| SCHEMBL25609123 | 0.77 | NR1D1 (0.43) | LDHAACHEL3MBTL1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312195-B2 | Cyclised conotoxin peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-12-25 | — | — | US | disclosed |
| US-20050256301-A1 | Cyclised conotoxin peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256301-A1 | Cyclised conotoxin peptides | VIP, CANX, IAPP | LDHA 4136/4885ACHE 1686/4885L3MBTL1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.